CDH2 and hepatocellular carcinoma: It has been recently shown that myricetin inhibited EMT in hepatocellular cancer cell line MHCC97H by increasing E-cadherin and decreasing N-cadherin and vimentin mRNA expression levels (Ma et al., 2019).